- Home
- HIND vs GTBP Comparison
HIND vs GTBP Comparison
Compare HIND & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIND | GTBP |
|---|---|---|
| Founded | N/A | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 12.1M |
| IPO Year | 2016 | 2016 |
Fundamental Metrics
Financial Performance| Metric | HIND | GTBP |
|---|---|---|
| Price | $2.30 | $0.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 57.8K | ★ 658.9K |
| Earning Date | N/A | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $0.39 |
| 52 Week High | $12.87 | $3.73 |
Technical Indicators
Market Signals| Indicator | HIND | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 40.69 | 47.16 |
| Support Level | $2.02 | $0.40 |
| Resistance Level | $2.93 | $0.59 |
| Average True Range (ATR) | 0.19 | 0.03 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 28.87 | 65.18 |
Price Performance
Historical ComparisonAbout HIND Vyome Holdings Inc.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.